Evaluation of fluorine-18-BPA-fructose for boron neutron capture treatment planning

George Kabalka, Gary T. Smith, Jonathan P. Dyke, William S. Reid, C. P.Desmond Longford, Tony G. Roberts, N. Kesavulu Reddy, Edward Buonocore, Karl Hubner

Research output: Contribution to journalArticle

75 Citations (Scopus)

Abstract

Boron neutron capture therapy (BNCT) using 4- [10B]boronophenylalanine-fructose (BPA-Fr) is in Phase II clinical trials to validate BNCT as a treatment for glioblastoma multiforme and melanoma. Successful BNCT depends on knowledge of the distribution of boron-containing agents in both tumor and normal tissue as currently determined by chemical confirmation of boron deposition in surgically removed malignant tissue before BNCT. Methods: We used PET to noninvasively obtain in vivo information on the pharmacokinetics of the 18F-labeled analog of BPA-Fr in two patients with glioblastoma multiforme. Time-activity curves generated from the bolus injection of 18F-BPA-Fr were convolved to simulate a continuous infusion used for BNCT therapy. Results: Distribution of 18F-BPA-Fr by PET was found to be consistent with tumor as identified by MR imaging. The 18F-BPA-Fr tumor-to-normal brain uptake ratio was 1.9 in Patient 1 and 3.1 in Patient 2 at 52 min after injection. The 18F-BPA-Fr uptake ratio in glioblastoma paralleled that of nonlabeled BPA-Fr seen in patients as previously determined by boron analysis of human glioblastoma tissue obtained from pre- BNCT surgical biopsy. Conclusion: Knowledge of the biodistribution of BPA-Fr enables pre-BNCT calculation of expected tissue dosimetry for a selected dose of BPA-Fr at a specific neutron exposure. Fluorine-18-BPA-Fr PET is capable of providing in vivo BPA-Fr biodistribution data that may prove valuable for patient selection and pre-BNCT treatment planning.

Original languageEnglish (US)
Pages (from-to)1762-1767
Number of pages6
JournalJournal of Nuclear Medicine
Volume38
Issue number11
StatePublished - Nov 1 1997

Fingerprint

Boron
Boron Neutron Capture Therapy
Fluorine
Neutrons
Fructose
Glioblastoma
Therapeutics
Neoplasms
Phase II Clinical Trials
Injections
Patient Selection
Melanoma
Pharmacokinetics
Biopsy

All Science Journal Classification (ASJC) codes

  • Radiology Nuclear Medicine and imaging

Cite this

Kabalka, G., Smith, G. T., Dyke, J. P., Reid, W. S., Longford, C. P. D., Roberts, T. G., ... Hubner, K. (1997). Evaluation of fluorine-18-BPA-fructose for boron neutron capture treatment planning. Journal of Nuclear Medicine, 38(11), 1762-1767.

Evaluation of fluorine-18-BPA-fructose for boron neutron capture treatment planning. / Kabalka, George; Smith, Gary T.; Dyke, Jonathan P.; Reid, William S.; Longford, C. P.Desmond; Roberts, Tony G.; Reddy, N. Kesavulu; Buonocore, Edward; Hubner, Karl.

In: Journal of Nuclear Medicine, Vol. 38, No. 11, 01.11.1997, p. 1762-1767.

Research output: Contribution to journalArticle

Kabalka, G, Smith, GT, Dyke, JP, Reid, WS, Longford, CPD, Roberts, TG, Reddy, NK, Buonocore, E & Hubner, K 1997, 'Evaluation of fluorine-18-BPA-fructose for boron neutron capture treatment planning', Journal of Nuclear Medicine, vol. 38, no. 11, pp. 1762-1767.
Kabalka G, Smith GT, Dyke JP, Reid WS, Longford CPD, Roberts TG et al. Evaluation of fluorine-18-BPA-fructose for boron neutron capture treatment planning. Journal of Nuclear Medicine. 1997 Nov 1;38(11):1762-1767.
Kabalka, George ; Smith, Gary T. ; Dyke, Jonathan P. ; Reid, William S. ; Longford, C. P.Desmond ; Roberts, Tony G. ; Reddy, N. Kesavulu ; Buonocore, Edward ; Hubner, Karl. / Evaluation of fluorine-18-BPA-fructose for boron neutron capture treatment planning. In: Journal of Nuclear Medicine. 1997 ; Vol. 38, No. 11. pp. 1762-1767.
@article{5705c1057bc3403480dae9880b94c8b7,
title = "Evaluation of fluorine-18-BPA-fructose for boron neutron capture treatment planning",
abstract = "Boron neutron capture therapy (BNCT) using 4- [10B]boronophenylalanine-fructose (BPA-Fr) is in Phase II clinical trials to validate BNCT as a treatment for glioblastoma multiforme and melanoma. Successful BNCT depends on knowledge of the distribution of boron-containing agents in both tumor and normal tissue as currently determined by chemical confirmation of boron deposition in surgically removed malignant tissue before BNCT. Methods: We used PET to noninvasively obtain in vivo information on the pharmacokinetics of the 18F-labeled analog of BPA-Fr in two patients with glioblastoma multiforme. Time-activity curves generated from the bolus injection of 18F-BPA-Fr were convolved to simulate a continuous infusion used for BNCT therapy. Results: Distribution of 18F-BPA-Fr by PET was found to be consistent with tumor as identified by MR imaging. The 18F-BPA-Fr tumor-to-normal brain uptake ratio was 1.9 in Patient 1 and 3.1 in Patient 2 at 52 min after injection. The 18F-BPA-Fr uptake ratio in glioblastoma paralleled that of nonlabeled BPA-Fr seen in patients as previously determined by boron analysis of human glioblastoma tissue obtained from pre- BNCT surgical biopsy. Conclusion: Knowledge of the biodistribution of BPA-Fr enables pre-BNCT calculation of expected tissue dosimetry for a selected dose of BPA-Fr at a specific neutron exposure. Fluorine-18-BPA-Fr PET is capable of providing in vivo BPA-Fr biodistribution data that may prove valuable for patient selection and pre-BNCT treatment planning.",
author = "George Kabalka and Smith, {Gary T.} and Dyke, {Jonathan P.} and Reid, {William S.} and Longford, {C. P.Desmond} and Roberts, {Tony G.} and Reddy, {N. Kesavulu} and Edward Buonocore and Karl Hubner",
year = "1997",
month = "11",
day = "1",
language = "English (US)",
volume = "38",
pages = "1762--1767",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",
number = "11",

}

TY - JOUR

T1 - Evaluation of fluorine-18-BPA-fructose for boron neutron capture treatment planning

AU - Kabalka, George

AU - Smith, Gary T.

AU - Dyke, Jonathan P.

AU - Reid, William S.

AU - Longford, C. P.Desmond

AU - Roberts, Tony G.

AU - Reddy, N. Kesavulu

AU - Buonocore, Edward

AU - Hubner, Karl

PY - 1997/11/1

Y1 - 1997/11/1

N2 - Boron neutron capture therapy (BNCT) using 4- [10B]boronophenylalanine-fructose (BPA-Fr) is in Phase II clinical trials to validate BNCT as a treatment for glioblastoma multiforme and melanoma. Successful BNCT depends on knowledge of the distribution of boron-containing agents in both tumor and normal tissue as currently determined by chemical confirmation of boron deposition in surgically removed malignant tissue before BNCT. Methods: We used PET to noninvasively obtain in vivo information on the pharmacokinetics of the 18F-labeled analog of BPA-Fr in two patients with glioblastoma multiforme. Time-activity curves generated from the bolus injection of 18F-BPA-Fr were convolved to simulate a continuous infusion used for BNCT therapy. Results: Distribution of 18F-BPA-Fr by PET was found to be consistent with tumor as identified by MR imaging. The 18F-BPA-Fr tumor-to-normal brain uptake ratio was 1.9 in Patient 1 and 3.1 in Patient 2 at 52 min after injection. The 18F-BPA-Fr uptake ratio in glioblastoma paralleled that of nonlabeled BPA-Fr seen in patients as previously determined by boron analysis of human glioblastoma tissue obtained from pre- BNCT surgical biopsy. Conclusion: Knowledge of the biodistribution of BPA-Fr enables pre-BNCT calculation of expected tissue dosimetry for a selected dose of BPA-Fr at a specific neutron exposure. Fluorine-18-BPA-Fr PET is capable of providing in vivo BPA-Fr biodistribution data that may prove valuable for patient selection and pre-BNCT treatment planning.

AB - Boron neutron capture therapy (BNCT) using 4- [10B]boronophenylalanine-fructose (BPA-Fr) is in Phase II clinical trials to validate BNCT as a treatment for glioblastoma multiforme and melanoma. Successful BNCT depends on knowledge of the distribution of boron-containing agents in both tumor and normal tissue as currently determined by chemical confirmation of boron deposition in surgically removed malignant tissue before BNCT. Methods: We used PET to noninvasively obtain in vivo information on the pharmacokinetics of the 18F-labeled analog of BPA-Fr in two patients with glioblastoma multiforme. Time-activity curves generated from the bolus injection of 18F-BPA-Fr were convolved to simulate a continuous infusion used for BNCT therapy. Results: Distribution of 18F-BPA-Fr by PET was found to be consistent with tumor as identified by MR imaging. The 18F-BPA-Fr tumor-to-normal brain uptake ratio was 1.9 in Patient 1 and 3.1 in Patient 2 at 52 min after injection. The 18F-BPA-Fr uptake ratio in glioblastoma paralleled that of nonlabeled BPA-Fr seen in patients as previously determined by boron analysis of human glioblastoma tissue obtained from pre- BNCT surgical biopsy. Conclusion: Knowledge of the biodistribution of BPA-Fr enables pre-BNCT calculation of expected tissue dosimetry for a selected dose of BPA-Fr at a specific neutron exposure. Fluorine-18-BPA-Fr PET is capable of providing in vivo BPA-Fr biodistribution data that may prove valuable for patient selection and pre-BNCT treatment planning.

UR - http://www.scopus.com/inward/record.url?scp=0030712915&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030712915&partnerID=8YFLogxK

M3 - Article

VL - 38

SP - 1762

EP - 1767

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

SN - 0161-5505

IS - 11

ER -